Rafael Guerrero
Psychiatry · Katy, TXNPI 1386600138
Payments from drug & device makers
Across 1,017 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$902
- Neos Therapeutics, LP$872
- plus $10K from 30 others
What the payments were for
- Food & beverage$18,16198%
- Education$4362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,597 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $190,708 |
| IngrezzaValbenazine Tosylate | 13 | $110,590 |
| PerserisRisperidone | 12 | $34,969 |
| CaplytaLumateperone Tosylate | 21 | $34,102 |
| SpravatoEsketamine Hcl | 12 | $27,282 |
| VraylarCariprazine Hcl | 14 | $23,177 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $14,452 |
| TrintellixVortioxetine Hydrobromide | 23 | $14,396 |
| Aripiprazole | 53 | $5,953 |
| Depakote ErDivalproex Sodium | 11 | $3,057 |
| Eszopiclone | 25 | $2,760 |
| Risperidone OdtRisperidone | 12 | $2,220 |
| Clonazepam | 132 | $2,093 |
| Paliperidone ErPaliperidone | 16 | $2,069 |
| FocalinDexmethylphenidate Hcl | 27 | $1,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $902 | $190,70812 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $652 | $110,59013 claims |
| Indivior Inc.Perseris | $251 | $34,96912 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,526 | $34,10221 claims |
| Johnson & JohnsonSpravato | $794 | $27,28212 claims |
| AbbVieVraylar | $1,971 | $23,17714 claims |
| Axsome Therapeutics, Inc.Auvelity | $488 | $14,45214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $742 | $14,39623 claims |
| Almatica Pharma LLCSertraline Hcl | $656 | $32832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Katy
- Vikram MehraKaty$1.2M
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.